(Q37871535)

24 August 2017

1 reference

title

Oral, direct thrombin and factor Xa inhibitors: the replacement for warfarin, leeches, and pig intestines? (English)

1 reference

24 August 2017

0 references

1 reference

Alexander Straub

1

1 reference

24 August 2017

Susanne Roehrig

series ordinal

2

1 reference

24 August 2017

Alexander Hillisch

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

29 April 2011

1 reference

Angewandte Chemie International Edition

24 August 2017

published in

0 references

volume

50

1 reference

24 August 2017

issue

20

1 reference

24 August 2017

page(s)

4574-4590

1 reference

Pathophysiology of venous thrombosis

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Evaluation of inhibitor constants and alkylation rates for a series of thrombin affinity labels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Structure-based design of novel potent nonpeptide thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Fluorine interactions at the thrombin active site: protein backbone fragments H-C(alpha)-C=O comprise a favorable C-F environment and interactions of C-F with electrophiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Entering the era of non-basic p1 site groups: discovery of Xarelto (Rivaroxaban).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Factor Xa inhibitors: next-generation antithrombotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Arginine mimetic structures in biologically active antagonists and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

pH-dependent binding modes observed in trypsin crystals: lessons for structure-based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Discovery of a tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

A medicinal chemist's guide to molecular interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part I: exploration of 5-6 fused rings as alternative S1 moieties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: exploration of 6-6 fused rings as alternative S1 moieties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Disposition of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'- (methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)- 1H-pyrazole-5-carboxamide (DPC 423) by novel metabolic pathways. Characterization of unusual metabolites by liquid chromatography/ma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

P450-mediated metabolism of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)- [1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole- 5-carboxamide (DPC 423) and its analogues to aldoximes. Characterization of glutathione conjugates of postu

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Phenyltriazolinones as potent factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Cation-pi interactions at the active site of factor Xa: dramatic enhancement upon stepwise N-alkylation of ammonium ions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Dual inhibitors of the blood coagulation enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Selective and dual action orally active inhibitors of thrombin and factor Xa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

The complete amino acid sequence of hirudin, a thrombin specific inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Dibasic (Amidinoaryl)propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

Structure- and property-based design of factor Xa inhibitors: Pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004575

21 January 2018

Identifiers

DOI

10.1002/ANIE.201004575

1 reference

24 August 2017

1 reference